In vitro effect of retinoids on calcineurin activity

Biochemical Pharmacology

Volumn 60, Issue 6, 2000, Pages 803-808

  Spannaus Martin, Donna J ^a   Martin, Bruce L ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Calcineurin; Calmodulin activated phosphatase; Retinoids

Indexed keywords

ALKALINE PHOSPHATASE; BACTERIAL ENZYME; CALCINEURIN; ETRETIN; RETINAL; RETINOIC ACID; RETINOID; RETINOL;

ARTICLE; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; PRECIPITATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BRAIN; CALCINEURIN; CATTLE; RETINALDEHYDE; RETINOIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TRETINOIN; VITAMIN A;

EID: 0034666702     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00407-X     Document Type: Article

References (34)

1. Liu J., Farmer J.D. Jr, Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:1991;807-815.
2. Swanson S.K.H., Born T., Zydowsky L.D., Cho H., Chang H.Y., Walsh C.T., Rusnak F. Cyclosporin-mediated inhibition of bovine calcineurin by cyclophilins A and B. Proc Natl Acad Sci USA. 89:1992;3741-3745.
3. McCaffrey P.G., Perrino B.A., Soderling T.R., Rao A. NF-ATp, a T lymphocyte DNA-binding protein that is a target for calcineurin and immunosuppressive drugs. J Biol Chem. 268:1993;3747-3752.
4. Lu Y.F., Tomizawa K., Moriwaki A., Hayashi Y., Tokuda M., Itano T., Hatase O., Matsui H. Calcineurin inhibitors, FK506 and cyclosporin A suppress the NMDA receptor-mediated potentials and LTP, but not depotentiation in the rat hippocampus. Brain Res. 729:1996;142-146.
5. A-mediated responses in acutely dissociated rat hippocampal neurons. Neurosci Lett. 215:1996;95-98.
6. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., Grant S.R., Olson E.N. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 93:1998;215-228.
7. Sussman M.A., Lim H.W., Gude N., Taigen T., Olson E.N., Robbins J., Colbert M.C., Guallberto A., Wieczorek D.F., Molkentin J.D. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 281:1998;1690-1693.
8. Chin E.R., Olson E.N., Richardson J.A., Yang Q., Humphries C., Shelton J.M., Wu H., Zhu W., Bassel-Duby R., Williams R.S. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev. 12:1998;2499-2509.
9. Batiuk T.D., Kung L., Halloran P.F. Evidence that calcineurin is rate-limiting for primary lymphocyte activation. J Clin Invest. 100:1997;1894-1901.
10. Martin B.L. Inhibition of calcineurin by the tyrphostin class of tyrosine kinase inhibitors. Biochem Pharmacol. 56:1998;483-488.
11. Sharma R.K., Taylor W.A., Wang J.H. Use of calmodulin affinity chromatography for purification of specific calmodulin-dependent enzymes. Methods Enzymol. 102:1983;210-219.
12. Pallen C.J., Wang J.H. Calmodulin-stimulated dephosphorylation of p-nitrophenyl phosphate and free phosphotyrosine by calcineurin. J Biol Chem. 258:1983;8550-8553.
13. Pallen C.J., Brown M.L., Matsui H., Mitchell K.J., Wang J.H. Survey of calcineurin activity towards nonprotein compounds and identification of phosphoenol pyruvate as a substrate. Biochem Biophys Res Commun. 131:1985;1256-1261.
14. Martin B.L., Pallen C.J., Wang J.H., Graves D.J. Use of fluorinated tyrosine phosphates to probe the substrate specificity of the low molecular weight phosphatase activity of calcineurin. J Biol Chem. 260:1985;14932-14937.
15. 2+-dependent modulator protein. Adv Cyclic Nucleotide Res. 10:1979;187-198.
16. 2+-induced hydrophobic site on calmodulin Application for purification of calmodulin by phenyl-Sepharose affinity chromatography . Biochem Biophys Res Commun. 104:1982;830-836.
17. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
18. Liu J., Albers M.W., Wandless T.J., Luan S., Alberg D.G., Belshaw P.J., Cohen P., MacKintosh C., Klee C.B., Schreiber S.L. Inhibition of T cell signaling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry. 31:1992;3896-3901.
19. Enan E., Matsumura F. Specific inhibition of calcineurin by type II synthetic pyrethroid insecticides. Biochem Pharmacol. 43:1992;1777-1784.
20. Enz A., Pombo-Villar E. Class II pyrethroids Noninhibitors of calcineurin . Biochem Pharmacol. 54:1997;321-323.
21. Berth-Jones J., Henderson C.A., Munro C.S., Chalmers R.J.G., Boffa M.J., Norris P.G., Friedmann P.S., Graham-Brown R.A.C., Dowd P.M., Marks R., Sumner M.J. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). Br J Dermatol. 136:1997;527-530.
22. Ben-Hassat H., Vardi D.V., Gazit A., Klaus S.N., Chaouat M., Hartzstark Z., Levitzki A. Tyrphostins suppress the growth of psoriatic keratinocytes. Exp Dermatol. 4:1995;82-88.
23. Gottlieb A.B. Immunologic mechanisms in psoriasis. J Am Acad Dermatol. 18:1988;1376-1380.
24. Kuwabara K., Shudo K., Hori Y. Novel synthetic retinoic acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels. FEBS Lett. 378:1996;153-156.
25. Cush J.J., Tugwell P., Weinblatt M., Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol. 26:1999;1176-1186.
26. Harris E.D. Jr. Retinoid therapy for rheumatoid arthritis. Ann Intern Med. 100:1984;146-147.
27. Ockenfels H.M., Nussbaum G., Schultewolter T., Mertins K., Wagner S.N., Goos M. Tyrosine phosphorylation in psoriatic T cells is modulated by drugs that induce or improve psoriasis. Dermatology. 191:1995;217-225.
28. Raynaud F., Leduc C., Anderson W.B., Evain-Brion D. Retinoid treatment of human psoriatic fibroblasts induces an increase in cyclic AMP-dependent protein kinase activity. J Invest Dermatol. 89:1987;105-110.
29. Raynaud F., Liapi C., Gerbaud P., Anderson W.B., Evain-Brion D. Effect of retinoic acid on cAMP dependent protein phosphorylation in psoriatic fibroblasts. Biochem Biophys Res Commun. 156:1988;263-268.
30. Migita K., Eguchi K., Aoyagi T., Tsukada T., Tsuboi M., Kawabe Y., Nagataki S. The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast. Clin Exp Immunol. 104:1996;86-91.
31. Tang B., Myers L.K., Rosloniec E.F., Whittington K.B., Stuart J.M., Kang A.H. Characterization of signal transduction through the TCR-ζ chain following T cell stimulation with analogue peptides of type II collagen 260-267. J Immunol. 160:1998;3135-3142.
32. Heng M.C., Song M.K., Heng M.K. Elevated phosphorylase kinase activity in psoriatic epidermis Correlation with increased phosphorylation and psoriatic activity . Br J Dermatol. 130:1994;298-306.
33. Rasmussen H.H., Celis J.E. Evidence for an altered protein kinase C (PKC) signaling pathway in psoriasis. J Invest Dermatol. 101:1993;560-566.
34. Kihira H., Hiasa A., Yamamoto M., Katayama N., Kuno T., Ohtsuka K., Shiku H., Nishiwaka M. Possible involvement of calcineurin in retinoic acid-induced inhibition of leukemic HL-60 cell proliferation. Int J Oncol. 12:1998;629-634.